secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-02-11T23:59:59+00:00
Accession:  0000914475-22-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine reports 2021 INGREZZA sales of $1.1B, guides 2022 sales $1.25-1.35B
------------------------------------------------------------------------------

- Total revenue FY 2021 $1.13B (+8% YoY); INGREZZA net sales $1.09B (+10% YoY).
- GAAP net income $89.6M ($0.92 diluted EPS); non-GAAP net income $185.8M ($1.90 diluted EPS).
- Q4 2021 GAAP net loss $7.3M ($0.08 loss per share) due to $100M Sosei Heptares upfront fee.
- 2022 INGREZZA guidance $1.25-1.35B (+20% YoY midpoint); minimal federal cash taxes expected in 2022.
- Phase III KINECT-HD valbenazine met primary endpoint; sNDA for Huntington chorea planned H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000009/0000914475-22-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000009/nbix-20220211.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer